Lung Cancer

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

Scarcely a week goes by without a report in the peer-reviewed medical literature suggesting that a novel somatic genomic alteration or a specific normal polymorphism is potentially relevant to achieving a desirable clinical outcome within cancer medicine.

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses continued maintenance therapy in lung cancer.

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.

A preliminary analysis has shown that eribulin mesylate failed to meet its primary endpoint of improving overall survival in pre-treated patients with advanced non-small cell lung cancer

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

At Memorial Sloan Kettering, we offer a variety of clinical trials for patients with mesothelioma at all stages of their disease.

The second-generation oral ALK inhibitor ceritinib (Zykadia; LDK378) demonstrated rapid and durable responses in patients with ALK-positive, metastatic, non–small cell lung cancer (NSCLC)-regardless of whether they had been previously treated with crizotinib-achieving overall response rates of 60% or more in each subgroup of patients who had received zero to three prior therapies for their advanced lung cancer.

Yelena Y. Janjigian, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses results of an early-phase study looking at afatinib and cetuximab for patients with EGFR-mutant lung cancer.

As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC).

New generations of potent ALK inhibitors have been designed with extensive CNS activity and the ability to overcome acquired resistance mutations.

Everett E. Vokes, MD, Giant of Cancer Care: Lung Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses PARP inhibitors as treatments for patients with lung cancer.

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy

Tyrosine kinase inhibitors (TKIs) are effective as single agents in EGFR-positive non-small cell lung cancer (NSCLC), but investigators continue to ask questions about how to improve the results of these agents.

Curative strategies for patients with advanced lung cancer remain elusive despite several exciting advancements, according to Paul A. Bunn Jr, MD, and Primo N. Lara Jr, MD, who delivered keynote lectures during the 15th Annual International Lung Cancer Congress.

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

The KRAS mutation in lung cancer is an especially thorny problem, as it is an indicator of a poor prognosis and has not, in the past, been targeted specifically by any medications.

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the utility of the vaccine tecemotide as treatment for non-small cell lung cancer.

Paul A. Bunn, Jr., MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the pros and cons of having companion diagnostic tests in lung cancer.

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population

James L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses new USPSTF recommendations for lung cancer screening.

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial

The 15th Annual International Lung Cancer Congress, which began today in Huntington Beach, California and will continue through Saturday, will offer an array of information presented by multidisciplinary experts-in a brand-new format.